- Home
- PUMP vs AKBA Comparison
PUMP vs AKBA Comparison
Compare PUMP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUMP
- AKBA
- Stock Information
- Founded
- PUMP 2007
- AKBA 2007
- Country
- PUMP United States
- AKBA United States
- Employees
- PUMP N/A
- AKBA N/A
- Industry
- PUMP Oilfield Services/Equipment
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- PUMP Energy
- AKBA Health Care
- Exchange
- PUMP Nasdaq
- AKBA Nasdaq
- Market Cap
- PUMP 550.9M
- AKBA 669.7M
- IPO Year
- PUMP 2017
- AKBA 2014
- Fundamental
- Price
- PUMP $5.40
- AKBA $3.03
- Analyst Decision
- PUMP Buy
- AKBA Strong Buy
- Analyst Count
- PUMP 5
- AKBA 4
- Target Price
- PUMP $9.75
- AKBA $6.63
- AVG Volume (30 Days)
- PUMP 1.4M
- AKBA 5.0M
- Earning Date
- PUMP 04-29-2025
- AKBA 05-08-2025
- Dividend Yield
- PUMP N/A
- AKBA N/A
- EPS Growth
- PUMP N/A
- AKBA N/A
- EPS
- PUMP N/A
- AKBA N/A
- Revenue
- PUMP $1,397,859,000.00
- AKBA $184,909,000.00
- Revenue This Year
- PUMP N/A
- AKBA $21.58
- Revenue Next Year
- PUMP $9.04
- AKBA $47.69
- P/E Ratio
- PUMP N/A
- AKBA N/A
- Revenue Growth
- PUMP N/A
- AKBA N/A
- 52 Week Low
- PUMP $4.61
- AKBA $0.80
- 52 Week High
- PUMP $11.17
- AKBA $3.14
- Technical
- Relative Strength Index (RSI)
- PUMP 44.36
- AKBA 71.68
- Support Level
- PUMP $5.27
- AKBA $2.76
- Resistance Level
- PUMP $5.74
- AKBA $3.14
- Average True Range (ATR)
- PUMP 0.23
- AKBA 0.15
- MACD
- PUMP 0.00
- AKBA 0.02
- Stochastic Oscillator
- PUMP 14.24
- AKBA 86.08
About PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.